Enabling In Vivo CAR-T: Targeted Engineering, High-Titer LVV Manufacturing, and T-Cell-Specific Delivery

Rethinking GMP CRISPR Manufacturing Services.

CRISPR technology has rapidly evolved from a Nobel Prize-winning discovery to a groundbreaking genetic medicine, exemplified by the recent approval of Casgevy for sickle cell disease. While CRISPR holds immense potential to treat various genetic diseases, manufacturing challenges remain a key hurdle. uBriGene has developed a pioneering in vitro transcription (IVT) sgRNA manufacturing platform that addresses limitations in scalability, quality control, sgRNA length, and environmental sustainability.